Italia markets closed

FTSE MIB
34.657,35
+318,03(+0,93%)
Dow Jones
39.512,84
+125,08(+0,32%)
Nasdaq
16.340,87
-5,40(-0,03%)
Nikkei 225
38.229,11
+155,13(+0,41%)
Petrolio
78,20
-1,06(-1,34%)
Bitcoin EUR
56.469,86
-1.869,90(-3,21%)

NovoCure Limited (NVCR)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.

Aggiungi a watchlist

16,47

+0,34

(+2,11%)

Alla chiusura: 04:00PM EDT

16,40

-0,07

(-0,43%)

Dopo ore:

04:47PM EDT

I prezzi di scambio non provengono da tutti i mercati

Capitalizzazione	1,772B
Beta (5 anni mensile)	0,49
Rapporto PE (ttm)	N/D
EPS (ttm)	-1,81
Prossima data utili	02 mag 2024
Rendimento e dividendo (futuro)	N/D (N/D)
Data ex dividendo	N/D
Stima target 1A	26,92

Tutte

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in